J E Oesterling

发表

The clinical usefulness of percent free-PSA.

A W Partin, J. Oesterling, A. Partin, 1996, Urology.

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.

C G Chute, G G Klee, J. Oesterling, 1995, JAMA.

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

A W Partin, M W Kattan, M. Kattan, 1997, JAMA.

A model for the number of cores per prostate biopsy based on patient age and prostate gland volume.

J. Oesterling, B. Gillespie, J E Oesterling, 1998, The Journal of urology.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

J. Oesterling, H. Lilja, T. Piironen, 2000, The Journal of urology.

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

C G Chute, H A Guess, J. Oesterling, 1993, JAMA.

Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association.

J. Oesterling, M. Resnick, I. Thompson, 1995, The Journal of urology.

Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia.

J. Oesterling, M. Barry, M J Barry, 1994, The Journal of urology.

Benign prostatic hyperplasia. Medical and minimally invasive treatment options.

J. Oesterling, J E Oesterling, J. E. Oesterling, 1995, The New England journal of medicine.

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

L K Lloyd, J. Oesterling, C. Roehrborn, 1996, Urology.

PSA and staging of localized prostate cancer.

J E Oesterling, E Kleer, E. Kleer, 1993, The Urologic clinics of North America.

Does the mode of questionnaire administration affect the reporting of urinary symptoms?

H A Guess, J. Oesterling, H. Guess, 1995, Urology.

Using prostate-specific antigen to eliminate the staging radionuclide bone scan.

J. Oesterling, Cheryl T. Lee, J E Oesterling, 1997, The Urologic clinics of North America.

Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate.

C G Chute, H A Guess, J. Oesterling, 1995, The Journal of urology.

Age-specific reference ranges for serum prostate-specific antigen.

J. Oesterling, J E Oesterling, 1995, The Canadian journal of urology.

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

H A Guess, J. Oesterling, R. Epstein, 1994, Urology.

Staging of prostate cancer.

D. Bostwick, J. Oesterling, R. Myers, 1994, Seminars in surgical oncology.

Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

J. Oesterling, J E Oesterling, J. E. Oesterling, 1991, The Journal of urology.

Prostate-specific antigen density.

J. Oesterling, J E Oesterling, M C Beduschi, 1997, The Urologic clinics of North America.

The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.

J. Oesterling, E. Bergstralh, E J Bergstralh, 1993, JAMA.

PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.

D. Bostwick, J. Oesterling, H. Zincke, 1993, The Urologic clinics of North America.

Ejaculation increases the serum prostate-specific antigen concentration.

J. Oesterling, M. Strawderman, S. Jacobsen, 1996, Urology.

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

J. Oesterling, A. Partin, A. Partin, 1999, The Journal of urology.